AGEN : Summary for Agenus Inc. - Yahoo Finance

U.S. Markets open in 7 hrs 9 mins

Agenus Inc. (AGEN)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.02+0.14 (+3.61%)
At close: 4:00PM EDT
People also watch
CTICARRYCRISEXELARIA
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close3.88
Open3.82
Bid3.89 x 2000
Ask4.40 x 10000
Day's Range3.80 - 4.05
52 Week Range2.97 - 7.49
Volume878,178
Avg. Volume1,188,109
Market Cap395.28M
Beta2.59
PE Ratio (TTM)-2.75
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Capital Cube11 hours ago

    ETFs with exposure to Agenus, Inc. : March 27, 2017

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to Agenus, Inc. Here are 5 ETFs with the largest exposure to AGEN-US. Comparing the performance and risk of Agenus, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • PR Newswire4 days ago

    Agenus to Participate at Two Upcoming Immuno-Oncology Conferences

    LEXINGTON, Mass., March 24, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced participation ...

  • Agenus, Inc. :AGEN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
    Capital Cube7 days ago

    Agenus, Inc. :AGEN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017

    Categories: Yahoo Finance Get free summary analysis Agenus, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Agenus, Inc. – Idera Pharmaceuticals, Inc., Cascadian Therapeutics Inc., GlaxoSmithKline plc Sponsored ADR, Merck & Co., Inc., Johnson & Johnson, ImmunoCellular Therapeutics, Ltd., Bristol-Myers Squibb Company and Celldex Therapeutics, ... Read more (Read more...)